- Home
- AHG vs VIR Comparison
AHG vs VIR Comparison
Compare AHG & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHG
- VIR
- Stock Information
- Founded
- AHG 2013
- VIR 2016
- Country
- AHG China
- VIR United States
- Employees
- AHG N/A
- VIR N/A
- Industry
- AHG Business Services
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- AHG Consumer Discretionary
- VIR Health Care
- Exchange
- AHG Nasdaq
- VIR Nasdaq
- Market Cap
- AHG 765.9M
- VIR 844.9M
- IPO Year
- AHG N/A
- VIR 2019
- Fundamental
- Price
- AHG $1.08
- VIR $5.43
- Analyst Decision
- AHG
- VIR Strong Buy
- Analyst Count
- AHG 0
- VIR 7
- Target Price
- AHG N/A
- VIR $32.86
- AVG Volume (30 Days)
- AHG 6.0K
- VIR 1.1M
- Earning Date
- AHG 07-15-2025
- VIR 07-31-2025
- Dividend Yield
- AHG N/A
- VIR N/A
- EPS Growth
- AHG N/A
- VIR N/A
- EPS
- AHG N/A
- VIR N/A
- Revenue
- AHG $8,454,946.00
- VIR $20,861,000.00
- Revenue This Year
- AHG N/A
- VIR N/A
- Revenue Next Year
- AHG N/A
- VIR N/A
- P/E Ratio
- AHG N/A
- VIR N/A
- Revenue Growth
- AHG 281.19
- VIR N/A
- 52 Week Low
- AHG $0.74
- VIR $4.32
- 52 Week High
- AHG $2.35
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- AHG 35.36
- VIR 56.02
- Support Level
- AHG $1.29
- VIR $4.91
- Resistance Level
- AHG $1.30
- VIR $5.35
- Average True Range (ATR)
- AHG 0.07
- VIR 0.26
- MACD
- AHG -0.02
- VIR 0.02
- Stochastic Oscillator
- AHG 0.00
- VIR 98.11
About AHG Akso Health Group ADS
Akso Health Group formerly Xiaobai Maimai Inc is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.